临床试验：利妥昔单抗用于早期抗 HLA Allo 肾同种异体移植受者-猫眼课题宝

临床试验：利妥昔单抗用于早期抗 HLA Allo 肾同种异体移植受者

批准号：

7718914

负责人：

MARTHA PAVLAKIS

金额：

$0.07万

依托单位：

BETH ISRAEL DEACONESS MEDICAL CENTER

依托单位国家：

美国

项目类别：

财政年份：

2008

资助国家：

美国

项目状态：

已结题

起止时间：

2008-04-01 至 2008-05-31

来源：

https://reporter.nih.gov/project-details/7718914

关键词：

B-Lymphocytes Chronic Clinical Trials Computer Retrieval of Information on Scientific Projects Database Effectiveness End Point Functional disorder Funding Grant Institution Randomized Research Research Personnel Resources Source United States National Institutes of Health kidney allograft randomized placebo controlled trial rituximab

项目摘要

项目成果

MARTHA PAVLAKIS的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, single-blinded, randomized, placebo-controlled trial. Centers will screen 1200-1400 subjects and will randomize a total of 134 subjects over 3 years. The primary endpoint of this study is the effectiveness of B-cell depletion by anti-CD20 mAb therapy in reducing progression of chronic renal allograft dysfunction by chronic humoral rejection.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文